Advanced Ovarian Cancer Clinical Trials

28 clinical trials for Advanced Ovarian Cancer across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Centralization and Oncologic Outcomes in Ovarian Cancer — RECRUITING
• A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha — RECRUITING · PHASE1
• Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer — RECRUITING · PHASE2
• SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS — COMPLETED · NA
• Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients — ACTIVE_NOT_RECRUITING · PHASE3
• Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients — COMPLETED · PHASE1
• Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. — ACTIVE_NOT_RECRUITING · PHASE3
• Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker — NOT_YET_RECRUITING · PHASE2
• Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer — NOT_YET_RECRUITING
• SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases — ACTIVE_NOT_RECRUITING · PHASE1
• Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel — COMPLETED · PHASE1
• A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer — COMPLETED
• Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer — NOT_YET_RECRUITING · PHASE3
• Plasmodium Immunotherapy for Advanced Ovarian Cancer — NOT_YET_RECRUITING · PHASE2
• The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer — OTHER · PHASE1
• Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer — NOT_YET_RECRUITING · PHASE2
• Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin — COMPLETED · PHASE2
• Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer — COMPLETED · NA
• Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer — OTHER · PHASE2
• Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations — COMPLETED · PHASE1
• A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer — TERMINATED · PHASE1
• The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial — COMPLETED · PHASE1
• Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer — COMPLETED
• Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer — OTHER · PHASE2
• Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer — COMPLETED · PHASE2
• Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors — COMPLETED · PHASE1

Refine this search